Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IO102-103 · IO-102

Vaccine (Peptide vaccine) · Immune activation · developed by IO Biotech

Phase 2 Most advanced trial

What is IO102-103?

IO102-103 is an investigational agent studied in head and neck squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IO-102
Drug type
Vaccine (Peptide vaccine)
Mechanism
Immune activation
Therapy area
Oncology
Developer
IO Biotech
In trials of
MRK
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
V74I849BP9

Conditions studied

Head and Neck Squamous Cell Carcinoma

Sources

Updated Nov 8, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.